Month: February 2021

Montrouge, France, le 22 février (07 h 30 CET), 2021DBV Technologies annonce la nomination de Michele F. Robertson au poste de Directrice Juridique GroupeDBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market : DBVT), une société biopharmaceutique en phase clinique, a annoncé aujourd’hui la nomination de Michele F. Robertson au poste de Directrice Juridique Groupe, à compter d’aujourd’hui. En sa qualité d’avocate expérimentée, Michele, en tant que Directrice Juridique Groupe, rapportera directement à Daniel Tassé, Directeur Général, et sera membre du Comité exécutif.« Michele nous apporte son expérience approfondie, démontrée dans de nombreux domaines juridiques et commerciaux dans le secteur biopharmaceutique. Son expérience sera essentielle pour notre développement scientifique, nos efforts réglementaires,...

Saint-Herblain (France), February 22, 2021 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need, today announced that it has initiated the clinical lot-to-lot consistency Phase 3 study for its single-shot chikungunya vaccine candidate, VLA1553. This study will run in parallel to the ongoing, pivotal Phase 3 study, VLA1553-301, which includes the determination of seroprotection based on an immunological surrogate1.The objective of this study is to show manufacturing consistency of the vaccine by demonstrating that three consecutively manufactured lots elicit equivalent immune responses measured by neutralizing antibody titers on Day 29 after vaccination. Study volunteers will be followed for a total of six months.Juan Carlos Jaramillo, M.D.,...

Utrecht (Netherlands) and Paris (France), February 22, 2021 – Atos today announced that it has completed the acquisition of Profit4SF, a Dutch-based technology and management consulting company specializing in Salesforce enterprise implementations for its customers across the Netherlands. With this transaction, Atos re-affirms its ambitions to grow its expertise on Salesforce technologies across the globe, following the acquisitions of Eagle Creek and Edifixio in 2020.On an operational level, the acquisition will enhance Atos’ Salesforce offering by bringing experienced consultants to the Atos team and strengthening the Salesforce Global Practice created by Atos to bring customers the full benefits of the world’s first customer relationship management platform. Founded in 2013 and headquartered in Utrecht, Profit4SF has more than...

Utrecht (Pays-Bas) et Paris (France), le 22 février 2021 – Atos annonce aujourd’hui avoir finalisé l’acquisition de Profit4SF, société néerlandaise de conseil en technologie et gestion d’entreprise spécialisée dans les implémentations Salesforce pour ses clients aux Pays-Bas. Avec cette opération qui fait suite à celles d’Eagle Creek et Edifixio en 2020, Atos réaffirme sa volonté de développer son expertise dans les technologies Salesforce à travers le monde.Sur le plan opérationnel, cette acquisition permettra d’améliorer l’offre Salesforce d’Atos en renforçant son équipe de consultants expérimentés, réunis au sein sa nouvelle Practice Globale Salesforce. Les clients d’Atos peuvent ainsi bénéficier d’un accompagnement personnalisé pour profiter de tous les avantages de la plus grande plate-forme de...

Saint-Herblain (France), 22 février 2021 – Valneva SE (“Valneva” ou “le Groupe”), société spécialisée dans les vaccins contre des maladies infectieuses générant d’importants besoins médicaux, a annoncé aujourd’hui avoir initié une étude visant à évaluer l’homogénéité des lots cliniques de Phase 3 de son candidat vaccin à injection unique contre le chikungunya, VLA1553.Cette étude sera conduite en parallèle de l’étude pivot de Phase 3 déjà en cours, VLA1553-301, qui porte notamment sur la détermination de la séroprotection sur la base de critères immunologiques1.L’objectif de cette nouvelle étude est de démontrer l’homogénéité de la fabrication du vaccin en montrant que trois lots fabriqués consécutivement provoquent des réponses immunitaires équivalentes en mesurant les titres d’anticorps neutralisants vingt-neuf jour après...

Broadening spectrum to include high growth opportunities in Bitcoin, digital currencies and blockchainAll time highs in Bitcoin, influx of investment and increased institutional adoption is creating a highly lucrative opportunityVinergy to acquire additional human capital to review and evaluate investment opportunities in the sectorVANCOUVER, British Columbia, Feb. 22, 2021 (GLOBE NEWSWIRE) — Vinergy Cannabis Capital Inc. (“Vinergy” or the “Company”) (CSE: VIN; OTCQB;VNNYF; FSE;1V7) is pleased to announce that it is updating and amending its current investment policy to broaden the spectrum of the types of investments it is focused on to include high impact and high growth opportunities in Bitcoin mining, Bitcoin derivatives, digital currencies, digital currency marketplaces and exchanges and blockchain, amongst others.As...

VANCOUVER, British Columbia and NEWPORT BEACH, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) — Clean Power Capital Corp. (CSE: MOVE)(FWB: 2K6)(OTC: MOTNF) (“Clean Power” or the “Company” or “MOVE”). The Company is pleased to provide additional information about how the onsite hydrogen production and dispensing technology being developed by PowerTap Hydrogen Fueling Corp. (“PowerTap”), an investee company of Clean Power, will be used in other commercial markers.PowerTap has commenced plans to commercialize its 3rd Generation units into new verticals such as commercial buses and trains, and has started initial discussions with various cities, states/provinces about partnerships. Subject to the progression of PowerTap’s plan to expand its product offering into commercial buses and trains, its 3rd generation onsite hydrogen production...

— 1stapproval of any checkpoint inhibitor in nasopharyngeal carcinoma in the world— 2ndindication approved for Toripalimab in ChinaSHANGHAI, China, Feb. 22, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) of China has granted a conditional approval to toripalimab for the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) after failure of at least two lines of prior systemic therapy. This is the first approval of immune checkpoint blockade therapy in NPC in the world and the second approved indication for toripalimab in China. In December 2018, Toripalimab obtained...

MANAGEMENT COMMENTARYSecond half of 2020 is characterized by continuation of COVID crisis. Salmon prices are 12-year low and compared to the same period last year, salmon prices are down 38% and rainbow trout is down by 22.5%. Adding to this global decrease in demand due to shutdown of HoReCa and you can call the situation as „perfect storm“. Companies who emerge from this crisis unscathed will be future winners. Arrival of vaccines is giving hope that we can see some normalization during 2nd half of 2021. 2022 will definitely be more profitable year in Fish farming as farmers can plan better the demand. Today’s farming volumes were planned before crisis and therefore there is massive oversupply in the market and most Fish farmers operate either at loss or at break-even. John Ross Jr has shown extraordinary resilience in current crisis...